157 related articles for article (PubMed ID: 11715936)
1. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Mikhailidis DP; Jagroon IA
Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
[No Abstract] [Full Text] [Related]
2. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
Knipscheer HC; de Valois JC; van den Ende B; Wouter ten Cate J; Kastelein JJ
Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
[TBL] [Abstract][Full Text] [Related]
3. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
Collinson PO; Hjelm CJ; Canepo-Anson R
Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
[No Abstract] [Full Text] [Related]
5. Fibrate treatment can increase serum creatinine levels.
Tsimihodimos V; Kakafika A; Elisaf M
Nephrol Dial Transplant; 2001 Jun; 16(6):1301. PubMed ID: 11390746
[No Abstract] [Full Text] [Related]
6. [Cytolytic hepatic damage caused by ciprofibrate].
Perault MC; Fievre JL; Dejean C; Martin A; Vandel B
Gastroenterol Clin Biol; 1992; 16(6-7):609. PubMed ID: 1526424
[No Abstract] [Full Text] [Related]
7. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
Liamis G; Kakafika A; Bairaktari E; Miltiadous G; Tsimihodimos V; Goudevenos J; Achimastos A; Elisaf M
Curr Med Res Opin; 2002; 18(3):125-8. PubMed ID: 12094821
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
Turpin G; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
[TBL] [Abstract][Full Text] [Related]
10. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
Harvengt C
Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
[No Abstract] [Full Text] [Related]
11. Ciprofibrate and lipid profile.
Chandler HA; Batchelor AJ
Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
[No Abstract] [Full Text] [Related]
12. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Olsson AG; Orö L
Atherosclerosis; 1982 Apr; 42(2-3):229-43. PubMed ID: 6951582
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of familial combined hyperlipidemia].
Bruckert E
Ann Endocrinol (Paris); 1997; 58(4):297-301. PubMed ID: 9436478
[No Abstract] [Full Text] [Related]
14. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Rizzo M; Berneis K
Curr Med Res Opin; 2007 May; 23(5):1103-11. PubMed ID: 17519077
[TBL] [Abstract][Full Text] [Related]
15. Statin-fibrate combinations in patients with combined hyperlipedemia.
Athyros VG; Papageorgiou AA; Kontopoulos AG
Atherosclerosis; 2001 Mar; 155(1):263-4. PubMed ID: 11293392
[No Abstract] [Full Text] [Related]
16. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
Francik R; Kryczyk J; Francik S
Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
[TBL] [Abstract][Full Text] [Related]
17. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
Chapman MJ; Bruckert E
Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
[TBL] [Abstract][Full Text] [Related]
18. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Bruckert E; Dejager S; Chapman MJ
Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Bruckert E; De Gennes JL; Malbecq W; Baigts F
Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
[TBL] [Abstract][Full Text] [Related]
20. Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment.
Ramachandran S; Giles PD; Hartland A
BMJ; 1997 May; 314(7094):1593. PubMed ID: 9186171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
